Transforming Disease Detection Through the Eyes

Cornea Sense

 Cornea Sense is developing a medical diagnostic device to help eye doctors diagnose and monitor eye and metabolic diseases by providing direct and specific ocular surface hydration data.

In short

 

Why Now

 

Eye care is undergoing a major shift, and current diagnostic tools are reaching their limits.

Cornea Sense sits at the intersection of these trends:

• Rising demand for early detection of diabetes, dry eye disease, and post-surgical complications
• Hospitals and clinics seeking non-invasive, software-integrated diagnostic tools
 

 

Traction & Milestones

 

• Technology developed at Aalto University
• PCT patent filed + new patent disclosures in pipeline
• Functional prototype validated on phantom models
• Transitioning to first human-eye measurements
• Strong clinical advisory network (Finland, EU, US)
• Incorporated January 2026

 

Investment Opportunity

 

The pre-seed round is closed. Cornea Sense has completed a €1.1M+ pre-seed financing round. The round combines private investment from Innovestor Angel CoFounder and a group of expierenced angel investors, including Matts Linder, eye surgeon, and Patrick Aisher, Chairman of Kinled Holding and Danube BioVentures, alongside support from a Business Finland R&D grant.

Funding will accelerate:


• Clinical validation and regulatory pathway (MDR Class IIa)
• Device miniaturisation and production design

Current goals: 


• Complete clinical readiness and human-data validation
• Set up pilot sites across Europe and the US
 

We welcome early conversations with:


• Medtech and diagnostics VCs
• Strategic ophthalmology and imaging investors
 

Proudly supported by